<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950426</url>
  </required_header>
  <id_info>
    <org_study_id>2021-000312-36</org_study_id>
    <nct_id>NCT04950426</nct_id>
  </id_info>
  <brief_title>Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome</brief_title>
  <acronym>PTSD-FMS</acronym>
  <official_title>Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Henri Laborit</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate a significant improvement in quality of life specific&#xD;
      to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid&#xD;
      posttraumatic stress disorder, treated with reconsolidation blockade.&#xD;
&#xD;
      Patients receive a treatment with propranolol associated with reconsolidation blockade of&#xD;
      traumatic story once a week during 6 weeks, with evaluation at inclusion and at 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 9, 2021</start_date>
  <completion_date type="Anticipated">September 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation therapy.</measure>
    <time_frame>3 months</time_frame>
    <description>Modification in quality of life in patients with fibromyalgia syndrome measured by the Fibromyalgia Impact Measurement Questionnaire (FIQ).&#xD;
FIQ minimal value:0 (minimum impact) FIQ maximal value: 100 (maximal impact)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Fibromyalgia Syndrome</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment with reconsolidation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.</description>
    <arm_group_label>Treatment with reconsolidation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult over 18 years old&#xD;
&#xD;
          -  Diagnosis of fibromyalgia syndrome according to ACR 2016 criteria&#xD;
&#xD;
          -  PCL-5 &gt; 44 suggesting the presence of a comorbid post-traumatic stress disorder&#xD;
&#xD;
          -  Meet the DSM-5 criteria for post-traumatic stress disorder secondary to exposure to a&#xD;
             traumatic event according to DSM-5 criteria, both unique or repeated and regardless of&#xD;
             the date or location of the traumatic event.&#xD;
&#xD;
          -  Pain relief treatment and/or psychotropic treatment stabilized for a period greater&#xD;
             than or equal to two months.&#xD;
&#xD;
          -  Signature of a consent form&#xD;
&#xD;
          -  Patient able to understand and read french&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychotic disorders&#xD;
&#xD;
          -  Unstable bipolar disorder&#xD;
&#xD;
          -  Patients with a systolic blood pressure &lt; 100 mmHg or heart rate &lt; 55 as established&#xD;
             during the initial visit&#xD;
&#xD;
          -  Significant anormal ECG&#xD;
&#xD;
          -  Medical contraindication to taking propranolol&#xD;
&#xD;
          -  Adverse reactions or previous intolerances to a beta blocker&#xD;
&#xD;
          -  Current intake of another beta blocker which can not be stopped during the protocol,&#xD;
             regardeless the galenic.&#xD;
&#xD;
          -  Current intake of a drug with potential contraindication with the propranolol,&#xD;
             according to the summary of product characteristics of the propranolol.&#xD;
&#xD;
          -  Patient under legal protection, under guardianship or under curatorship&#xD;
&#xD;
          -  Patient having suffered a head trauma for less than a year or with clinical symptoms&#xD;
             and neurological sequelae&#xD;
&#xD;
          -  Known severe suicide risk (MINI-S and medical exam)&#xD;
&#xD;
          -  Current opioid addiction or alcohol dependence&#xD;
&#xD;
          -  Patients treated for less than 2 months with antidepressants or painkillers&#xD;
&#xD;
          -  Patients unafiliated to a social health care&#xD;
&#xD;
          -  Woman who is pregnant or breast-feeding or whithout efficient contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yassir ELFAIROUQI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Henri Laborit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yassir ELFAIROUQI, Dr</last_name>
    <phone>0033 5 16 52 61 18</phone>
    <email>yassir.elfairouqi@ch-poitiers.fr</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

